FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran
This article was originally published in The Pink Sheet Daily
Executive Summary
For unknown reasons, SSNRI spending weeks in regulatory limbo.
You may also be interested in...
Whistleblower Investigation Delayed Approval Of Forest's Savella
FDA missed the user fee goal date for Forest's Savella (milnacipran) due to an investigation of late-breaking whistleblower allegations, review documents for the fibromyalgia therapy show
Whistleblower Investigation Delayed Approval Of Forest's Savella
FDA missed the user fee goal date for Forest's Savella (milnacipran) due to an investigation of late-breaking whistleblower allegations, review documents for the fibromyalgia therapy show
Forest Savella’s Launch For Fibromyalgia: Many Sales Forces, Single Claim
Forest's promotional messaging for the launch of its fibromyalgia drug Savella (milnacipran) has a somewhat unusual emphasis - the product's limited utility